Phospho-MYB (S12) Antibody

What is Phospho-MYB (S12) Antibody and what does it specifically detect?

Phospho-MYB (S12) antibody is a polyclonal antibody that specifically recognizes the c-Myb protein only when phosphorylated at the Serine 12 residue. This antibody detects endogenous levels of c-Myb protein exclusively in its phosphorylated state at S12, making it valuable for studying phosphorylation-dependent signaling pathways. The antibody is typically produced against synthesized peptides derived from human MYB around the phosphorylation site of Ser12, usually within the amino acid range of 1-50 .

What is the biological significance of MYB phosphorylation at Serine 12?

MYB functions as a transcriptional activator and DNA-binding protein that specifically recognizes the sequence 5'-YAACGTG-3'. The protein plays an important role in controlling proliferation and differentiation of hematopoietic progenitor cells . Phosphorylation is a critical post-translational modification that often regulates protein function, and in cancer phenotypes, abnormal hyper-phosphorylation of target proteins is frequently observed due to dysregulated kinase activity . Studying the phosphorylation status at Ser12 can provide insights into how MYB activity is regulated in normal and disease states.

What are the typical specifications of commercially available Phospho-MYB (S12) antibodies?

Most commercially available Phospho-MYB (S12) antibodies share these specifications:

These antibodies are typically affinity-purified from rabbit antiserum using epitope-specific immunogens .

How should I validate the specificity of a Phospho-MYB (S12) antibody before using it in my experiments?

Validating phospho-specific antibodies is crucial to ensure they discriminate between phosphorylated and non-phosphorylated versions of the protein. A recommended validation approach includes:

• Dephosphorylation assay: Treat your protein lysate with phosphatase and assess if this treatment abrogates immunoreactivity when using the phospho-specific antibody. This confirms the antibody is truly phospho-specific.

• Mobility shift assessment: Observe if dephosphorylation generates an electrophoretic mobility shift consistent with the removal of phosphate groups in an immunoblot.

• Peptide competition assay: Perform immunoblotting or immunohistochemistry in the presence of the immunizing phosphopeptide, which should compete for antibody binding and reduce or eliminate the signal.

• Control samples: Include both positive controls (cells/tissues known to express phosphorylated MYB at S12) and negative controls (cells/tissues with minimal phosphorylation) .

The Western blot validation shown in the search results demonstrates this approach, where lane 1 shows a clear band at the expected 72 kDa, while lane 2 (with immunizing phosphopeptide) shows no band, confirming specificity .

What are the optimal protocols for using Phospho-MYB (S12) antibody in Western blotting?

For optimal Western blotting results with Phospho-MYB (S12) antibody:

• Sample preparation: Extract proteins from cells at 90-95% confluence using a lysis buffer containing phosphatase inhibitors to preserve phosphorylation status.

• Protein loading: Load 20-30 μg of protein per lane (as demonstrated in validation studies using 30 μg of HeLa cell extracts).

• Antibody dilution: Use a 1:500-1:2000 dilution of the primary antibody in TBST with 3-5% BSA or non-fat milk.

• Incubation: Incubate with primary antibody overnight at 4°C for optimal results.

• Detection: Use HRP-conjugated secondary antibodies and a chemiluminescent kit compatible with your detection system.

• Expected results: The predicted band size for MYB is approximately 72 kDa.

• Controls: Always include appropriate controls, including total MYB antibody in parallel samples to normalize phosphorylation levels .

What considerations should be made when using Phospho-MYB (S12) antibody for immunohistochemistry?

When performing immunohistochemistry with Phospho-MYB (S12) antibody:

• Tissue preparation: Use formalin-fixed, paraffin-embedded (FFPE) sections. Ensure tissues were fixed promptly to preserve phosphorylation status.

• Antigen retrieval: Perform heat-induced epitope retrieval, typically using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0).

• Antibody dilution: Use at 1:100-1:300 dilution as recommended by manufacturers.

• Blocking: Block with appropriate serum (usually 5-10% normal goat serum) to reduce background.

• Controls: Include positive control tissues (like human heart tissue, which has been validated with this antibody) and negative controls (primary antibody omission or non-immune IgG).

• Specificity validation: Run parallel sections with the immunizing phosphopeptide to confirm specificity of staining.

• Subcellular localization: MYB is predominantly nuclear, so staining should be primarily observed in the nucleus .

How can I optimize detection of phosphorylated MYB in samples with low expression levels?

For samples with low phospho-MYB expression:

• Increase protein concentration: Load more total protein (up to 50-60 μg) for Western blotting.

• Adjust antibody incubation: Consider longer incubation times (24-48 hours at 4°C) or slightly higher antibody concentrations.

• Enhance signal detection: Use more sensitive chemiluminescent substrates designed for low-abundance proteins.

• Immunoprecipitation: Consider immunoprecipitating MYB first, then probing with the phospho-specific antibody to concentrate the target protein.

• Phosphatase inhibitors: Ensure your lysis buffer contains appropriate phosphatase inhibitors (sodium fluoride, sodium orthovanadate, etc.) to preserve phosphorylation.

• Stimulation: For cell culture experiments, consider treatments that may increase MYB phosphorylation at S12.

• Signal amplification: For IHC/IF, use signal amplification systems like tyramine signal amplification or polymer-based detection systems .

What types of cell lines and tissue samples are most appropriate for studying MYB S12 phosphorylation?

Based on MYB's biological role and expression patterns:

• Hematopoietic cell lines: Since MYB plays an important role in hematopoietic progenitor cell proliferation and differentiation, cell lines like K562, HL-60, and Jurkat are appropriate.

• Cancer cell lines: HeLa cells have been validated for phospho-MYB (S12) detection as shown in the search results.

• Tissue samples: Human heart tissue has been validated for IHC applications with phospho-MYB (S12) antibody.

• Primary tissues: Bone marrow, lymphoid tissues, and colonic epithelium typically express MYB and would be suitable for studying its phosphorylation.

• Species considerations: The antibodies are typically reactive to human and mouse samples, so cell lines and tissues from these species are appropriate .

How should I design experiments to study the dynamics of MYB S12 phosphorylation in response to stimuli?

To study dynamic phosphorylation changes:

• Time course experiments: Treat cells with relevant stimuli and collect samples at multiple time points (e.g., 0, 5, 15, 30, 60 minutes, 2, 6, 24 hours).

• Dose-response studies: Treat cells with increasing concentrations of stimulus to determine threshold effects on phosphorylation.

• Inhibitor studies: Use kinase inhibitors to block phosphorylation pathways and identify the responsible kinases.

• Phosphatase inhibition: Compare samples with and without phosphatase inhibitors to assess turnover rates.

• Quantification: Perform densitometric analysis of Western blots, normalizing phospho-MYB to total MYB levels.

• Parallel assays: Combine Western blotting with functional assays to correlate phosphorylation status with transcriptional activity.

• In vivo models: For more physiologically relevant contexts, consider animal models where appropriate stimuli can be applied systemically .

What are common issues encountered when using Phospho-MYB (S12) antibody and how can they be resolved?

Common issues and solutions:

• No signal detected:

  • Verify protein expression in your sample with total MYB antibody

  • Ensure phosphorylation status is preserved with proper inhibitors

  • Increase antibody concentration or protein loading

  • Verify secondary antibody compatibility

• Multiple bands/non-specific binding:

  • Increase blocking time/concentration

  • Optimize antibody dilution (try more dilute)

  • Increase washing steps

  • Perform peptide competition assay to identify specific bands

• High background:

  • Use fresher antibody dilutions

  • Increase blocking time

  • Reduce antibody concentration

  • Use more stringent washing conditions

• Inconsistent results:

  • Standardize protein extraction and handling protocols

  • Avoid repeated freeze-thaw cycles of antibody

  • Prepare fresh working solutions

  • Standardize exposure times in detection

How should phosphorylation at S12 be quantified and normalized for accurate comparative analysis?

For accurate quantification and normalization:

• Normalization strategy:

  • Always normalize phospho-MYB (S12) to total MYB protein levels

  • Run parallel blots or strip and reprobe with total MYB antibody

  • Calculate the phospho-MYB/total MYB ratio for each condition

• Loading controls:

  • Include appropriate housekeeping proteins (β-actin, GAPDH) to ensure equal loading

  • Consider using stain-free technology or total protein normalization for more accurate results

• Technical replicates:

  • Perform at least three technical replicates for Western blot quantification

  • Use appropriate statistical analysis to determine significance

• Standard curves:

  • For absolute quantification, consider using recombinant phosphorylated standards if available

• Image analysis:

  • Use linear range exposure times for quantification

  • Employ appropriate software (ImageJ, etc.) for densitometry

  • Avoid saturated signals that would lead to inaccurate quantification

How do I interpret discrepancies between phospho-MYB detection across different experimental methods?

When facing discrepancies between methods:

• Method sensitivity differences:

  • Western blotting may be more sensitive than IHC for detecting low levels of phosphorylation

  • ELISA may provide more quantitative results than visual methods

• Sample preparation effects:

  • Fixation and embedding for IHC may affect phospho-epitope accessibility

  • Protein denaturation for Western blotting may expose epitopes differently

• Spatial vs. bulk analysis:

  • IHC provides spatial information but may be less quantitative

  • Western blotting provides bulk analysis without spatial resolution

• Antibody performance variation:

  • Some antibodies perform better in certain applications (native vs. denatured conditions)

  • Validate each application independently

• Resolution approach:

  • Use complementary methods to verify findings

  • Consider phosphatase treatment controls in all methods

  • Use multiple antibodies targeting the same phospho-site when possible

How does MYB S12 phosphorylation relate to other post-translational modifications of the protein?

The relationship between S12 phosphorylation and other modifications:

• Cross-regulation: Phosphorylation at S12 may influence or be influenced by other phosphorylation sites on MYB. Consider studying multiple phosphorylation sites simultaneously.

• Modification crosstalk: Investigate potential crosstalk between phosphorylation and other modifications like acetylation, ubiquitination, or SUMOylation, which may affect MYB stability or activity.

• Sequential modifications: Consider whether S12 phosphorylation is a priming event for other modifications or vice versa.

• Modification mapping: For comprehensive studies, consider using mass spectrometry to map all modifications and their relative abundances.

• Functional domains: Assess how S12 phosphorylation (located within amino acids 1-50) may affect other functional domains of MYB, including its DNA-binding capacity or protein-protein interactions .

What are the most appropriate experimental models to study the functional consequences of MYB S12 phosphorylation?

To study functional consequences:

• Site-directed mutagenesis: Generate S12A (phospho-null) and S12E/S12D (phospho-mimetic) mutants to study the effects of constitutive absence or presence of phosphorylation.

• Inducible systems: Create cell lines with inducible wild-type and mutant MYB expression to study acute effects of phosphorylation status changes.

• CRISPR/Cas9 knock-in: Generate cell lines or animal models with endogenous MYB mutations at S12 for physiologically relevant studies.

• Transcriptional reporter assays: Use MYB-responsive promoter constructs to assess how S12 phosphorylation affects transcriptional activity.

• Protein-protein interaction studies: Perform co-immunoprecipitation or proximity ligation assays to determine how S12 phosphorylation affects MYB's interaction partners.

• ChIP-seq analysis: Investigate how S12 phosphorylation impacts MYB genomic occupancy and target gene regulation .

How can advanced phosphoproteomics approaches complement antibody-based detection of MYB S12 phosphorylation?

Integrating phosphoproteomics with antibody-based methods:

• Global phosphorylation profiling: Use mass spectrometry-based phosphoproteomics to identify all phosphorylation sites on MYB and their relative stoichiometry.

• Kinase identification: Employ kinase prediction algorithms and in vitro kinase assays to identify kinases responsible for S12 phosphorylation.

• Phosphorylation dynamics: Use SILAC or TMT labeling with mass spectrometry to quantify changes in phosphorylation over time or in response to stimuli.

• Validation workflow: Use phosphoproteomics for discovery and antibody-based methods for targeted validation in larger sample sets.

• Phosphatase identification: Perform phosphatase inhibitor screens to identify enzymes responsible for dephosphorylating S12.

• Pathway analysis: Integrate phosphoproteomics data with signaling pathway analysis to place S12 phosphorylation in a broader cellular context.

• Cross-validation: Use mass spectrometry results to validate antibody specificity and vice versa .

What methodological approaches can be used to study the relationship between MYB S12 phosphorylation and its DNA-binding capacity?

To investigate the impact on DNA-binding:

• Electrophoretic Mobility Shift Assay (EMSA): Compare DNA-binding properties of phosphorylated vs. non-phosphorylated MYB protein to the consensus sequence 5'-YAACGTG-3'.

• Chromatin Immunoprecipitation (ChIP): Use phospho-specific antibodies for ChIP to identify genomic regions bound by phosphorylated MYB.

• DNA-protein interaction assays: Employ fluorescence polarization or surface plasmon resonance to quantify binding affinities as a function of phosphorylation.

• Structural studies: If feasible, use X-ray crystallography or NMR to determine how S12 phosphorylation affects the structural conformation of MYB's DNA-binding domain.

• In silico modeling: Perform molecular dynamics simulations to predict how S12 phosphorylation might alter protein conformation and DNA-binding properties.

• Transcriptional reporter assays: Design reporters with wild-type and mutated MYB binding sites to assess sequence specificity changes induced by phosphorylation .